AVLN Avalyn Pharma Inc. Common Stock

QT27

Latest market price

26.23

+0.63+2.45%

Overview Short InterestFilings

AVLNQT27Avalyn Pharma Inc. Common Stock·NASDAQ

Overview Short InterestFilings

26.23+2.45%

Loading chart...

Signal & projected range

Falling wedge — reversalHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

QURE+1.11%$23.23 RARE+2.58%$16.72 NUVB+3.49%$4.75 TRAX+1.51%$45.73 NTLA+3.52%$12.07 ABSI+5.06%$10.18 URGN+1.22%$34.78 MAZE+5.46%$32.03

Snapshot

Index	—	P/E	—	EPS (ttm)	—	Insider Own	0.07%	Shs Outstand	44.33M	Perf Week	-5.67%

Market Cap	1.13B	Forward P/E	—	EPS next Y	-2.96	Insider Trans	0.00%	Shs Float	14.45M	Perf Month	-8.99%

Enterprise Value	799.93M	PEG	—	EPS next Q	-0.71			Short Float	16.29%	Perf Quarter	-16.69%

Income	-85.00M	P/S	—	EPS this Y	—			Short Ratio	9.71	Perf Half Y	-11.94%

Sales	0.00	P/B	2.85	EPS next Y	—	ROA	-13.12%	Short Interest	2.35M	Perf YTD	-1.54%

Book/sh	8.98	P/C	3.22	EPS next 5Y	—	ROE	-83.23%	52W High	40.17 -34.71%	Perf Year	—

Cash/sh	7.94	P/FCF	—	EPS past 3/5Y	—	ROIC	-14.25%	52W Low	22.24 17.93%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	5.77% 6.88%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	1.84	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	33.10	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	44.07	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	33.10	EPS Q/Q	95.51%	SMA20	1.39%	Beta	-0.06	Target Price	60.00

Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	—	SMA50	-14.38%	Rel Volume	1.53	Prev Close	25.60

Employees	55	LT Debt/Eq	0.04	Earnings	Nov 11	SMA200	-14.55%	Avg Volume	291.65K	Price	26.23

IPO Date	Apr 30, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-29.51% —	Net Debt/EBITDA	—	Volume	445,062	Change	2.45%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-02-26	Initiated	Raymond James	Outperform	$60
Aug-13-26	Reiterated	Morgan Stanley	Overweight	$53 → $57
May-26-26	Initiated	Evercore ISI	Outperform	$51
May-26-26	Initiated	Morgan Stanley	Overweight	$53
May-25-26	Initiated	Jefferies	Buy	$52
May-25-26	Initiated	Guggenheim	Buy	$80

Latest News· Times ET

Oct-13-26

Oct-13-2611:24AM

Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.Yahoo

Oct-02-26

Oct-02-2604:24AM

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga

Oct-01-26

Oct-01-2606:15AM

Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated “Moderate Buy” by Wall Street Analystsdefenseworld.net

Sep-23-26

Sep-23-2605:15AM

Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too PriceyYahoo

Sep-21-26

Sep-21-2609:00AM

Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profileglobenewswire.com

Sep-16-26

Sep-16-2604:01PM

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directorsglobenewswire.com

Sep-14-26

Sep-14-2612:41PM

Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha

Sep-08-26

Sep-08-2608:00AM

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conferenceglobenewswire.com

08:00AM

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosisglobenewswire.com

Aug-24-26

Aug-24-2604:01PM

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026globenewswire.com

Aug-13-26

Aug-13-2606:16AM

Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57Benzinga

Aug-12-26

Aug-12-2608:00AM

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlightsglobenewswire.com

04:13AM

Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) EstimateBenzinga

Company

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		0
Gross Profit		0
Selling, General and Administrative Excl. Other		15
Research and Development		77
Other Operating Expense		-1
Operating Income		-91
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		6
Net Income Before Taxes		-85
Income Taxes		0
Consolidated Net Income		-85
Net Income From Continuing Operations		-85
Net Income		-85
EPS (Recurring)		-2.04
EPS (Basic, Before Extraordinaries)		-2.04
EPS (Diluted)		-2.04
EBITDA		-91
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		42
Market Capitalization		—
Operating Lease Expense		—

Insider Trading Volume

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.